The Clinical and Economic Benefits Associated With Novel Multi-Cancer Early Detection Tests: Conference Highlights from the 2022 ISPOR Annual Meeting

Program Description
There is a consensus among oncology care providers on the need for new technologies with the ability to detect cancer early so that treatments can be initiated at an earlier stage, which can potentially increase patients’ survival. Detecting cancer early, when it is at its most treatable stage, is the focus of a new international research collaboration. New blood-based technologies, known as multi-cancer early detection (MCED) tests, are entering the market and can identify multiple cancers early and simultaneously. Managed care professionals can ensure appropriate use of novel methods to detect cancer early, including those cancers that do not have a screening test and are often diagnosed in advanced stages, to support efforts that aim to reduce overall indirect and direct costs for patients and the healthcare system. This article will summarize MCED tests and recap data presented at the ISPOR 2022 Annual Meeting to keep managed care professionals up to date with the latest information on emerging technologies involved in the early detection of cancer.

Target Audience: Managed care pharmacists
Type of Activity: Application
Release date: August 12, 2022
Expiration date: August 12, 2023
Time to complete activity: 1.5 hours
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Determine current recommended screening tools for cancer and the role of novel and emerging multi-cancer early detection tests.
• Examine the common barriers and disparities that may contribute to low rates of cancer screenings.
• Explore recent clinical updates for emerging and novel multi-cancer early detection technologies including information presented at the 2022 ISPOR Annual Meeting.
• Identify the role of managed care professionals in incorporating the use of novel tools for early cancer detection into clinical practice to improve outcomes and potentially reduce rates of mortality due to early intervention.